Australia markets close in 4 hours 18 minutes

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
59.16+0.26 (+0.44%)
At close: 04:00PM EDT
59.26 +0.10 (+0.17%)
After hours: 07:59PM EDT

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000

IndustryDrug Manufacturers—General
Full-time employees34,300

Key executives

NameTitlePayExercisedYear born
Dr. Giovanni Caforio M.D.Chairman & CEO5.76MN/A1965
Mr. David V. ElkinsExec. VP & CFO2.72M2.83M1968
Dr. Christopher S. Boerner Ph.D.Exec. VP, COO & Director2.62MN/A1971
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel2.66MN/A1961
Mr. Greg MeyersExec. VP and Chief Digital & Technology OfficerN/AN/A1973
Mr. Timothy PowerVP & Head of Investor RelationsN/AN/AN/A
Ms. Cari GallmanSr. VP & Chief Compliance and Ethics OfficerN/AN/AN/A
Ms. Ann M. Powell JudgeExec. VP & Chief HR OfficerN/AN/A1966
Dr. Fouad Namouni M.D.Head of Oncology Devel.N/AN/A1969
Mr. Samit Hirawat M.D.Exec. VP & Chief Medical Officer of Drug Devel.N/AN/A1969
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Corporate governance

Bristol-Myers Squibb Company’s ISS governance QualityScore as of 1 September 2023 is 2. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.